Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Aug 19, 2011

Premium

The Swiss Institute of Bioinformatics has appointed David de Graaf and Alexey Nesvizhskii to serve on its scientific advisory board.

De Graaf is CEO of Selventa. Prior to that he was vice president of biotherapeutics and integrative biology at Boehringer-Ingelheim. He has also held positions at Pfizer, AstraZeneca, and the Whitehead Institute's Center for Genome Research.

Nesvizhskii is an assistant professor at the University of Michigan, Ann Arbor, where he specializes in quantitative proteomics, with a focus on developing computational methods for processing and extracting biological information from complex proteomic datasets. His lab develops computational tools and statistical methods for mass spectrometry-based peptide and protein identification and quantification; works on establishing guidelines and standards for proteomic data analysis and publication; and creates public databases and proteomic data repositories.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.